Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00907972 · ClinicalTrials.gov registry record · Phase 2
The Effects of Vitamin D and Bone Loss in Parkinson's Disease
A Phase 2 study, sponsored by Memorial Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 23
- Enrollment target
NCT00907972 is a Phase 2 study that has completed, run by Memorial Medical Center. The registered enrollment target is 23 participants.
The verdict
NCT00907972, a Phase 2 study, has completed, sponsored by Memorial Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 23 participants
- Enrollment target
Study Summary
Health care burdens from neurodegenerative diseases are expected to increase disproportionately. Increasing age also predisposes this same population to other chronic diseases including osteoporosis, a progressive systemic skeletal disease characterized by low bone mass, which leads to an increase susceptibility to fractures. In the United States, 44 million people are estimated to be at risk for osteoporosis and low bone mass emphasizing the enormity of this public health problem. Parkinson's disease is a progressive neurodegenerative disorder affecting about 1 million people. Evidence indicates that Parkinson's disease patients are at a higher risk for low bone mineral density, which can contribute to increased fractures compared to healthy subjects. In fact, several risk factors of osteoporosis in patients with PD have been identified, including advanced stages of PD, low body mass index, inadequate sunlight exposure and decreased vitamin D levels. Some or all of these factors in conjunction with decreased immobilization that may occur with PD, put patients at increased risks for fractures. Few studies however have examined bone markers in PD patients. Even fewer studies have examined the impact of Vitamin D supplementation on bone metabolism and mineralization in PD patients. Vitamin D is an essential component in bone health, promoting calcium absorption in the gut and maintaining adequate serum calcium and phosphate concentrations, which enable normal mineralization of bone.
Interventions
- OTHER Placebo
- DIETARY_SUPPLEMENT Vitamin D3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2009-09 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00907972
The ClinicalTrials.gov registry entry for NCT00907972 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Medical Center, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00907972 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00907972 about?
NCT00907972 is a clinical study titled "The Effects of Vitamin D and Bone Loss in Parkinson's Disease". Health care burdens from neurodegenerative diseases are expected to increase disproportionately. Increasing age also predisposes this same population to other chronic diseases including osteoporosis, a progressive systemic skeletal disease characterized by low bone mass, which leads to an increase s...
What is the current status of trial NCT00907972?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2009-09. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00907972?
The interventions under investigation include: Placebo (OTHER), Vitamin D3 (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT00907972?
This trial is sponsored by Memorial Medical Center, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.